Page last updated: 2024-09-05

sorafenib and Hypoxia

sorafenib has been researched along with Hypoxia in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.35)29.6817
2010's13 (56.52)24.3611
2020's9 (39.13)2.80

Authors

AuthorsStudies
Du, FH; Li, YL; Li, ZD; Wu, J; Wu, LW; Zeng, LH; Zhang, C; Zhang, MM1
Chen, Z; He, Q; Lin, N; Xie, Q; Yan, F; Yang, B; Ye, S; Yuan, T; Zhang, B; Zhu, H1
Feng, T; Huang, X; Lai, C; Li, Y; Shang, J; Shi, Y; Yang, Q; Yao, Y; Zhang, Z; Zhong, D1
Luo, J; Mu, X; Wang, Z; Yang, Q; Zhao, Y1
Li, Y; Liu, M; Wang, Z; Zhao, Y; Zheng, Y1
He, Z; Kong, Z; Li, S; Luo, C; Sun, J; Wang, Z; Ye, H; Zhang, S; Zheng, Y1
Abdel-Reheim, MA; Aboregela, AM; Al-Ameer, AY; Alamri, MMS; Alfaifi, J; Cavalu, S; Hasan, AM; Hashish, AA; Khalid, TBA; Mohammed, OA; Saber, S; Saleh, LA; Senbel, A1
Dai, Z; Deng, Y; Dong, L; Liang, L; Zan, Y1
Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L1
Bao, MH; Wong, CC1
Fang, C; Gao, P; Geng, P; Guo, L; Hu, C; Li, E; Liu, Y; Sun, M; Tang, L; Wang, C; Wang, J; Wang, Y; Xu, G; Yin, P; Yu, J; Zeng, J; Zhuang, Z1
Fondevila, F; García-Palomo, A; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C1
Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H1
Ewig, JM; Iyer, P; Mayer, JL1
Waxman, DJ; Zhang, K1
Luo, CL; Wu, XH; Zhao, CX1
Fang, Q; Liu, S; Sun, J; Xu, H; Zhan, C; Zhang, S; Zhang, Y; Zhao, L1
Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A1
Cramer, T; Daskalow, K; Decker, G; Gonzalez-Carmona, MA; Hirt, S; Raskopf, E; Sauerbruch, T; Schmitz, V; Standop, J; Vogt, A1
Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y1
Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M1
Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T1
Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D1

Reviews

2 review(s) available for sorafenib and Hypoxia

ArticleYear
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
    Cells, 2021, 07-06, Volume: 10, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cellular Reprogramming; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immune Checkpoint Inhibitors; Liver Neoplasms; Metabolic Networks and Pathways; Nivolumab; Protein Kinase Inhibitors; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Tumor Microenvironment

2021
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
    Experimental & molecular medicine, 2018, 10-12, Volume: 50, Issue:10

    Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Sorafenib; Tumor Microenvironment

2018

Other Studies

21 other study(ies) available for sorafenib and Hypoxia

ArticleYear
DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
    International journal of oncology, 2022, Volume: 60, Issue:4

    Topics: Dyrk Kinases; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phenylurea Compounds; Protective Factors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2022
CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
    BMC cancer, 2022, Apr-19, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides

2022
ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
    Cancer medicine, 2023, Volume: 12, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Sorafenib

2023
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
    Journal of colloid and interface science, 2022, Dec-15, Volume: 628, Issue:Pt B

    Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicumarol; Female; Glutathione; Humans; Hypoxia; Micelles; NAD; NADP; Nitroimidazoles; Oxygen; Phosphates; Polyethylene Glycols; Polymers; Quinones; Sorafenib; Thioredoxins

2022
Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
    Journal of colloid and interface science, 2023, Volume: 641

    Topics: Animals; Antioxidants; Cell Line, Tumor; Coenzymes; Glutathione; Humans; Hypoxia; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Sorafenib

2023
Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication.
    Cell reports. Medicine, 2023, 04-18, Volume: 4, Issue:4

    Topics: Animals; Humans; Hypoxia; Lighting; Mice; Neoplasms; Sorafenib

2023
Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel therapeutic approach.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 164

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hypoxia; Liver Neoplasms; Mice; Necroptosis; Sorafenib

2023
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
    Drug delivery, 2019, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catechols; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Glucosides; Hep G2 Cells; Humans; Hypoxia; Liver Neoplasms; Mice; Nanoparticles; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
    Biochemical pharmacology, 2020, Volume: 178

    Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib

2020
Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 01-15, Volume: 24, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Energy Metabolism; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Metabolome; Metabolomics; Phenotype; Proline; Sorafenib; Xenograft Model Antitumor Assays

2018
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
    Magnetic resonance imaging, 2019, Volume: 57

    Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib

2019
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
    Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:1

    Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2014
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays

2013
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1

    Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured

2015
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Virchows Archiv : an international journal of pathology, 2017, Volume: 470, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemokine CXCL12; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Hypoxia; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sorafenib; Survival Analysis; Tissue Array Analysis; Young Adult

2017
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
    Current pharmaceutical biotechnology, 2012, Volume: 13, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Feedback, Physiological; Hypoxia; MAP Kinase Kinase 4; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2012
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
    International journal of oncology, 2012, Volume: 41, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    International journal of oncology, 2013, Volume: 42, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Humans; Hypoxia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2013
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays

2013
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A

2007